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Summary.-The i.v. injection of high doses (3 mg) of BCG into C3H mice bearing a
transplantable 3-methylcholanthrene-induced fibrosarcoma caused the regression
of a significant proportion. This effect was most evident when the BCG was injected
on the day of the graft, or 7 days later. The injection of this agent either 14 days
before the graft, or in low doses (0.1 or 0 5 mg), or directly into the tumour (i.t.) only
prolonged the survival of the animals. Spleen cells from systemic high-dose BCG-
treated mice were found to exert a strong nonspecific cytostatic effect in vitro that
was not an artefact of the test conditions, and was not expressed by cells from low-
dose animals. The cytostatic effect was shown to be caused by cells with the
characteristics of macrophages, i.e. they were strongly adherent, unaffected by
treatment with anti-Thy 1.2+C', radioresistant but heat-sensitive, and were detected
in BCG-treated "B" mice.
The spleens of high-dose BCG-treated mice also contained suppressor cells that
were capable of inhibiting the in vitro reactivity of normal T cells to PHA. Like the
cytostatic effect, this suppressor activity was not detected in low-dose mice, and
the cells responsible had the properties of macrophages; the effect was lost after the
removal of adherent cells by sequential exposure to plastic and colloidal iron, but
was conserved after treatment with anti-Thy 1.2+C'. T-cell-deprived animals, such
as "B" or nude mice, also developed suppressor-cell activity when treated with
systemic high-dose BCG.
Close parallels became evident between the in vivo anti-tumour activity of BCG,
the in vitro cytostatic effect, and the suppressor-cell activity. We here discuss the
possible role of suppressor cells in the mechanism of action of this agent.
A MAJOR ADVANCE in the field of
immunology during the past few years
has been the concept that immune reac-
tions are controlled by negative feed-back
mechanisms through suppressor cells (Ger-
shon & Kondo, 1971). In many immuno-
logical model systems suppressor cells of
different types, particularly suppressor T
cells (Ha et al., 1974), but also B cells
(Zembala et al., 1976) and macrophages
(Nelson, 1976), have been implicated.
There have been a number of reports that
suppressor cells may also play a role in
the immunosuppression found in some
experimental tumour models (Greene et
al., 1977). In this respect, various bacterial
vaccines such as BCG have been demon-
strated to enhance nonspecifically a num-
ber of immune responses (Miller et al.,
1973) and are reported to produce a
clinical improvement in some cases of
leukaemia (Mathe et al., 1974) and mela-
noma (Morton et al., 1970). Also in various
animal models, like the one described in
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this report, BCGr treatment can exert a
marked curative effect (Hanna et al.,
1972). Studies in our laboratories have
demonstrated that these agents can also
induce nonspecific cell-mediated suppres-
sion of a variety of responses such as
mitogen stimulation (Orbach-Arbouys &
Poupon, 1978) or GvH and mixed lympho-
cyte reactions (Orbach-Arbouys & Castes,
1980).
In an attempt to elucidate the possible
role of suppressor cells in the anti-tumour
activity of BCG, we performed a series of
experiments to correlate this effect with
the in vitro cytostatic activity of various
spleen-cell populations from BCG-treated
mice. We demonstrated that systemic
high-dose BCG exerted an anti-tumour
effect in vivo, and induced the appearance
of a cell population that was both cyto-
static and suppressive for mitogen re-
sponse. These cells weire induced, and
expressed their activity, in the absence of
T cells, and had the properties of macro-
phages.
MATERIALS AND METHODS
Muice
6-8-wk-eek-old specific-pathogen-free C57-
BL/6 mice were obtained from the broeding
centre ofthe Centre National de la Recherche
Scientifique, Orleans, France. C3H/He mice
wvere provided by the Institut de Recherches
Scientifiques sur le Cancer, Villejuif, France.
Nude (nu/nu) mice were maintained in
deliberately outbred colonies under barrier-
protected conditions by Dr J. C. Salomon.
IRSC, Villejuif, France. "B" mice were pre-
pared by irradiation with 6 Gy, 1 week after
thymectomy, and ith 3 Gy a week later
(A. J. S. Davies, personal communication).
The mice ere not reconstituted with marrow,
as this can contain T cells. Such mice mounted
no detectable plaque-forming cell (PFC)
responses to injections of sheep erythrocytes,
but did so against DNP-flagellin.
Tunmours
McC3-1 and McB6-1 were fibrosarcomas
induced in C3H/He and C57BL/6 mice
respectively by the i.m. injection of 1 mg
3-methylcholanthrene, and maintained by
serial isogenic transplantation and freezing
of various passages. Tumour grafts Awere per-
formed ventrally by the s.c. introduction of
small pieces (,1 mm3) of non-necrotic tissue
via a trocar needle. The day of grafting wvas
taken as Day 0 in all experiments.
BCG
"Immuno BCG", which retains 950o
viability after 3 months storage at 4°C, wvas
kindly provided by the Pasteur Institute
(Paris, France) and injected as described in
the results. High doses (3 mg) i.v. caused
marked splenomegaly and hepatomegaly,
viz., spleen weights of 180 and 450 mg on
Days 7 and 14 respectively, and liver wNeights
of 1-6 and 2-6 g on these days (controls: 95 mg
and 1P3 g respectively).
Cell preparations
Spleen, cells. Spleens from groups of 4
mice wvere aseptically removed, placed in
Medium 199 (Eurobio, France) and gently
squeezed between 2 sterile glass slides. The
cell suspensions thus obtained wvere then
filtered through gauze and washed wvith cold
sterile Medium 199. For subsequent tests the
suspensions wvere prepared in RPMI 1640
(Eurobio, France) supplemented wvith 2mM
glutamine (Gibco, Grand Island, New- York)
and containing 500 fresh human AB serum
(decomplemented by heating at 56°C for
30 min), 100 i.u./ml penicillin and 100 ,Lg/ml
streptomycin. When irradiated, the cells
received 15 Gy delivered by a caesium bomb
(Gravaton Industries, Gosport, Hampshire).
Enriched T cells. T cells wvere isolated
with nylon w-ool columns using the technique
of Julius et al. (1973). Anti-Thy 1.2 serumn
(Lespinats & Poupon, 1977) plus guinea-pig
complement killed 94%o of the normal T-
enriched suspension. This population is
referred to throughout this report as nylon-
purified T cells, or simply spleen T cells. Such
preparations obtained from BCG-treated
mice contained only 7500 of cells killed by
this treatment.
Adherent spleen cells. 108 spleen cells in
10 ml of RPMI Awith 50 inactivated foetal
calf serum (Eurobio. France) wvere incubated
horizontally in a 250ml plastic bottle (Falcon
Plastics, California, U.S.A.); then after 60
min the supernatant was discarded and the
cells adhering to the plastic were rinsed
twrice with PBS, incubated 3-10 min with
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5 ml of Ca- and Mg free Earle's medium
(Gibco) containing 0-02% EDTA. The cells
were harvested, washed and adjusted to a
concentration of 5 x 106/ml.
Depletion of adherent spleen cells usi,ng
carbon yl-irotIparticles. 2 x 107 spleen cells
in 20 ml of nutrient medium supplemented
with 10% FCS were incubated at 37°C for 30
rnin w%Aith 50 mg of carbonyl-iron particles
(particles E; GAF, Louvres, France) in a
250ml plastic bottle (Falcon Plastics). The
cells adhering to the particles were mag-
netically removed by the procedure of Gold-
stein & Blomgren (1973). Treatment ith
anti-Thy 1.2+C' killed 3%0 of these cells.
Depletion? of Thy 1.2 cells. Anti-Thy 1.2
serum wNas prepared as described by Reif &
Allen (1964). This antiserum killed 95%o of
normal thymocytes hen incubated for 30
muin at a dilution of 1:27 in the presence of
guinea-pig complement. Lyophilized guinea-
pig serum w% as obtained from Institut Pasteur
Production, Paris, France. and was absorbed
wN-ith agar as described by Cohen & Schlesinger
(1970).
In vitro Culture technriques
Cytostatic test. Continuously cultivated
McC3-1 and McB6-1 tumour cells, growing
exponentially in RPMI 1640 supplemented
with 500 inactivated foetal calf serum, were
harvested by trypsinization and used as
targets in cytostatic assays.
The Imethod used was as described by
Lespinats & Poupon (1977) with minor modi-
fications. The tumour cells were washed and
adjusted to 2x 104 cells/ml in RPMI 1640
plus 2% inactivated foetal calf serum, 2mM
glutamine and antibiotics. 100,ul aliquots of
the lymphocyte suspensions were added to
2500 tumour cells at ratios of 12-5:1, 25:1 and
50:1, in a total volume of 200 jA in micro-
titre plates (Falcon, 3040). All cultures were
performed in triplicate. The microplates were
covered and incubated at 37°C in an atmo-
sphere of5%o CO2 95s0 air for 72 h, after which
I ,uCi of [3H]dT (TMM48, Commissariat de
l'Energie Atomique, Saclay, France, sp. act.
27 Ci/mmol) wNas added to each well during
the last 5 h of incubation. Cultures were
harvested with a multiple automated sample
harvester (MASH, Microbiological Associ-
ates, Bethesda, MA, U.S.A.) on glass-fibre
filters (Reeve Angels, Clifton, N.Y.) which
were placed in toluene plus Omnifluor (NEN,
Dreieichhaim, West Germany) and counted
in a Packard counter.
Mitogen responsiveness.-To test the re-
sponsiveness of spleen-cell populations to
mitogens. 2-5 or 5 x 105 cells were placed in
wells of Falcon 3040 microplates in a volume
of 250 ,ul. The mitogen dose used was that
found to be optimal for stimulation ofnormal
spleen cells: 04 ug per w%ell of PHA HA16
(Wellcome Research Laboratories, Becken-
ham, England).
To demonstrate the suppressive properties
of cells from BCG-treated mice, 5 x 105 cells
from normal or BCG-treated animals were
cultivated with 2-5 x 105 normal T cells and
the same amount of PHA was added as pre-
viously. All cultures were performed in
triplicate and incubated for 48 h in an atmo-
sphere of5% CO2 in air. Five h before the end
of the culture, 1 ,uCi of [3H]dT w%ias added to
each well. The cells were harvested on glass-
fibre filters, as described above, and the
results expressed as mean ct/min of triplicate
samples.
The suppressive effect of one population of
spleen cells (B) against another (A) was calcu-
lated by the formula:
ct/min (A+B) stimulated-
ct/min (A+B) unstimulated
et/mmn (A) stimulated -
ct/min (A) unstimulated
Preliminary studies demonstrated that the
results of tests performed in this way were
inot influenced by factors such as cell crowding
or nutritional alterations, and the optimal
PHA concentration was not changed, even
after BCG treatment.
Statistical methods.-The statistical signifi-
cance of results obtained in survival experi-
ments, cytostatic assays and mitogen stimu-
lation were analysed by the t test. The exact
method of calculating significance by the x2
test, using Yates' correction for small sample
sizes, was also used in the analysis of survival
data.
RESULTS
Anti-tuamour activity of BCG as measured
in vitro
BCG was injected at high (3 mg) or
lowr (0-1 or 0 5 mg) i.v. doses into mice
bearing the transplantable MeC3-1 fibro-
sarcoma. The BCG was injected either
on the day of the graft (Day 0), 14 days
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TABLE I.-Anti-tumour activity of BCG
administered systemically against the
McC3-1 tumour of C3H mice
TABLE II. In vitro cytostatic effect of
different cell populations from BCG-
treated mice on McB6-1 tumour cells
BCG
treatment
None
3 mg, Day -14
3 mg, Day Ot
3 mg, Day + 7
0.1 mg, Day 0
0 5 mg, Day + 7
2 x 1-5 mg,
Days 10+17§
St
t Day 0=Day of graf
t Of the mice that die
§ In this experiment
rather than i.v.
*P=0.006. **P.<O.
Survival time: Spleen cells
irvival (days) (50:1
0/11 35 0+ 4-4 Exp. tumour cell)
2/7 61-8 + 28-9** 1 None
5/7** f42 Normal
V106 BCG (3 mg)
5/10* 59-7 + 5 0** Normal adherent
0/7 54-7 + 9-2** BCG adherent
0/7 52-8 + 4 0** 2 Normal
0/9 52.3+3-5** BCG
Normal after anti
't. Thy 1.2+C'
d. BCG after anti
the BCG was injected i.t., Thy 1.2+C
3 Untreated
01. "B" mice
BCG "B" mice
4 Normal
before (Day - 14) or 7 days after (Day 7).
In Table I, presenting the results of one
of our experiments, it can be seen that
all the untreated animals died about 35
days after grafting. When 3 mg BCG was
injected on Day - 14, only 2/7 of the
tumours were rejected. Although this
proportion was not statistically significant,
the survival of the animals that died was
significantly lengthened. When the high
dose of BCG was injected on Day 0, 5/7
animals survived, this proportion being
statistically significant, and the mean time
ofdeath ofthe remainder was considerably
delayed. The injection of 3 mg BCG on
Day 7 caused both a significant tumour
rejection (5/10) and an increase in survival
time of the mice that died. Low doses of
BCG on Day 0 (0 1 mg) or Day 7 (0.5 mg)
had no curative effect, though they did
prolong life. It is of interest to note that
when 1-5 mg of BCG was injected twice,
with an interval of 7 days, into small
growing tumours about 10 days after
grafting (diameter 5 mm), there was
no rejection in 9 mice, though the mean
survival time was increased.
Anti-tumour activity of BCG as measured
in vitro
A series of experiments was performed
inwhich the cytostatic activity ofdifferent
cell populations from normal and BCG-
BUtG (u a mg)
*P<0.001.
[3H]-dT
incorporation
(ct/min)
29963 + 2058
36131+ 4082
8026 + 629
19791+ 4761
3816+ 642
265132 + 30047
149300 + 40583
235834 + 25176
100080 + 35475
105532+ 12011
32135+ 4135
124030 + 30613
155938 + 52210
Inhibition
by BCG
78*
81*
44*
58*
69*
-NS
treated animals was measured on MC-
induced C57B1/6 fibrosarcoma cells culti-
vated in vitro. The BCG was administered
i.v. at high dose (3 mg) and low (0.5 mg).
This cytotoxicity was also tested for its
sensitivity to irradiation (15 Gy) or heat-
ing (56°C, 30 min).
Table II presents the results of 4
representative experiments, in which it
can be seen (Exp. 1) that whole spleen-cell
preparations from high-dose BCG animals
inhibited the DNA synthesis of tumour
cells with which they were co-cultivated
in vitro.
This cytostatic effect was also exerted
by the adherent cells from such popula-
tions, and treatment with anti-Thy 1.2+
C' did not diminish their activity (Exp. 2).
It can also be seen (Exp. 3) that the
spleen cells from high-dose BCG-treated
"B" mice were cytostatic to the growth
of McB6-1 tumour cells.
In contrast to these results, cells from
low-dose BCG animals had no significant
effect in these tests (Exp. 4).
The figure demonstrates that the cyto-
stasis was not abolished when the whole
(or adherent) spleen cells were irradiated
(15 Gy) before culture. In contrast, heating
at 56°C for 30 min eliminated this effect.
No toxicity of the heated lymphoid-cell
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Fect of irradiation (15 Gy) or lheating (56 C, 30 min) of spleen cells from control or BCG-
treated (3 mg, i.v.) mice on [3H]dT incorporation by culturedl tumour cells.
preparations was detected, and heat-
inactivated normal spleen cells had no
inhibitory activity. In fact, increased
DNA synthesis by the cultured tumour
cells was found when heated cells were
added, possibly because of nutritional
factors. This effect was also noted when
irradiated cells from normal animals were
added to the cultures (Fig. 1).
Responsiveness tomitogen
It had been previously demonstrated
in our laboratories that the i.v. injection
of high doses of BCG into mice led to a
series of modifications of the in vitro
reactivity of lymphoid cells (Orbach-
Arbouys & Poupon, 1978). We therefore
extended our earlier studies of the de-
velopment of cells capable of suppressing
responses to PHA, and attempted to
confirm their identity.
Suppression by whole and adherent spleen-
cell populations from BCG-treated mice of
T-cell response to PHA
To determine whether the depression
of mitogen responsiveness of spleen cells
from high-dose BCG mice was an active
phenomenon, such cells from BCG-treated
animals were co-cultivated with normal T
cells, and the response of the mixed popu-
lation to PHA was measured. It can be
seen in Table III that the addition of
unfractionated spleen cells from high-dose
BCG mice diminished the response of the
normal T cells to this mitogen.
In a similar manner, when adherent
spleen cells from high-dose BCG mice were
added to normal T cells, there was a
severe depression of the response, whereas
adherent cells from normal mice had
virtually no effect.
This suppression persisted when the
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TABLE III.-Suppression of PHA responses by various spleen cell populations from
BCOG-treated mice
Spleen cells
(2:1 T cells)
Exp. 1 None
Normal t
BCG t
Adherent normal
Adherent BCG
Normal after anti Thy 1.2 +C'
BCG after anti Thy 1.2+C'
BCG T cells (Fa-Fe)*
Exp. 2 None
Normal
Low-dose BCG
+PHA
259162+ 17251
1999 + 1944
12721+ 2052
9244+ 1832
13513+ 1131
23766 + 570
141291 + 33493
222801 + 16072
97716+ 16388
Added to normal T cells
%PHA Suppression 00
by BCG
179195+ 15234
123674+ 17873
21691 + 365
151945 + 10868
5053 + 605
335266 + 9389
97151+ 1271
136459 + 31273
199047 + 9383
176906 + 59953
145026 + 28887
89-5**
96-7**
74-5**
- NS
23-4 NS
t The spontaneous incorporation by normal spleen cells in Exp. 1 was 6268 + 385 and of the BCG population 12600+ 672.
* Fa-Fe: Falcon plastic-colloidal iron purified T cells. ** P < 0-001.
TABLE IV.-Suppression ofPHA responses by high-dose BCG treated "B" or nude mouse
spleen cellpopulations
Added to normal T cellst
t ~ o
Spleen cells
None
Untreated "B" mice
BCG "B" mice
Untreated nude mice
BCG nude mice
+ PHA
15445 + 8261*
12885+ 1892*
43497 + 208*
10562 + 102
+PHA
64191 + 5770
96181 + 6180
32379 + 3468
74635 + 273
27283 + 1650
% suppression
by BCG
69-8**
57-7**
* Background of untreated "B" mice was: 26699 + 13694 and of nude mice: 30647 + 175. ** P< 0-001.
spleen cells were treated with anti-Thy
1.2 serum +C'. Alternatively, when highly
purified T-cell preparations were obtained
bythe removal of cells adhering to plastic
and colloid iron, no suppression was
observed. It should be noted that T cells
prepared by passage through nylon
columns were previously found to show
some suppressive effects (Orbach-Arbouys
& Poupon, 1978), possibly owing to the
presence of some residual adherent cells.
It can also be seen in Table III that
mice treated with low doses of BCG (0.5
mg) didnot develop significant suppressive
activity, whether the BCG was injected
14 or 21 days before the experiment. When
the spleen cells of such mice were tested
6 weeks after injection, a low but signifi-
cant (38%, P <0.01) suppression was
detected (results not presented).
It is of interest that the spontaneous
[3H]dT incorporation by normal spleen
cells was significantly lower than that of
the BCGpopulation in all ourexperiments.
Suppression of T-cell PHA responses by
spleen cells from BCG-treated B and nude
mice
In the light of the previous results, it
was thought important to determine
whether in fact T cells were necessary for
the generation or expression of the sup-
pressive effect on PHA responsiveness.
In Table IV it can be seen that B mice,
that effectively lacked PHA responses,
when treated with high doses of BCG
developed cells in their spleens that were
capable of suppressing the PHA response
of normal T cells. Similarly, BCG-treated
nude mice developed suppressive activity
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in their spleen-cell populations. It is
interesting that normal nude mice had
very little spleen-cell response indeed to
PHA, and the treated mice even less.
DISCUSSION
An anti-tumour effect of BCG in
experimental animal models has often been
reported (Hanna et al., 1972), but in many
systems this effect is prophylactic rather
than therapeutic (Finklestein et al., 1972).
When, however, therapeutic effects were
found against solid tumours, it was usually
necessary also to inject the BCG directly
into the lesion (Hanna et al., 1972). In our
experiments with a solid transplantable
:3-methylcholanthrene-induced fibrosar-
coma of C3H mice, a significant anti-
tumour effect was found when high doses
of BCG were injected systemically at the
same time as, or 7 days after, the graft.
This protection was expressed as a
significant proportion of the animals con-
trolling and subsequently rejecting their
tumours. Even the animals that died
survived longer. In this model, high-dose
systemic BCG exerted much less anti-
tumour activity when applied prophylac-
tically. Also, the intra-tumoural injection
of BCG exerted very little protection,
detectable only as a lengthened survival
time after grafting. The fact that BCG
administered systemically exerted aneffect
in this model, but not in many others, may
be explained by the requirement for a high
dose (3 mg); lower doses (0.1 or 0 5 mg)
that are commonly used had no curative
effects, though they did increase survival
times. It is of interest to note here that
animals that had rejected their tumour
grafts after BCG treatment were resistant
to further challenge grafts, whereas only
about half of the animals that had been
surgically cured of their tumour rejected a
second graft, (results not presented). This
observation can be interpreted to mean
that high-dose systemic BCG activates the
immune mechanism, or at least allows
longer and more effective contact of the
animal with the tumour antigens.
We decided, however, to examine in
more detail nonspecific mechanisms that
might contribute to BCG-stimulated
tumour control. Considering the well
documented effect of BCG on the reticulo-
endothelial system (Hibbs, 1975) we evalu-
ated more precisely the role of the macro-
phage.
We chose a cytostatic assay to examine
any nonspecific in vitro anti-tumour effects
of high-dose systemic BCG, and also
studied the suppressive effect of spleen
cells from such animals on T-cell PHA
response. We found that spleen cells from
animals treated systemically with high
(but not low) doses of BCG greatly in-
hibited the proliferation of cultured fibro-
sarcoma cells and PHA-stimulated lym-
phoid cells. The cells responsible were
found to be strongly adherent to plastic,
and the activity was removed by the
sequential exposure of the spleen cell
population to plastic and colloidal iron.
In earlier studies (Orbach-Arbouys &
Poupon, 1978) it was reported that, in
addition to the adherent fraction, sup-
pressive and cytostatic activities were
found in T-cell populations that had been
prepared by passage through nylon-wool
columns. In the present study, however,
we demonstrated that only 75%o of such
preparations expressed the surfacemarkers
of T cells, in contrast to 9400 in cell
populations obtainedfrom normalanimals.
The apparent contamination ofthe former
may represent T cells that were not
expressing Thy-1.2 anitigen due to their
stage of proliferation or differentiation, or
non-T cells that were weakly adherent for
similar reasons.
We found that the cytostatic and
suppressive activities were not affected
by treatment with anti-Thy 1.2+C', were
not sensitive to irradiation, but were lost
upon heating. Confirmation of the non-T-
cell character of the cells responsible, and
their independence ofa functional thymus,
was obtained by our studies of BCG-
treated "B" or nude mice.
The cytostatic and suppressive cells
have, therefore, the properties of macro-
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phages. Similar results have been reported
in other systems (Klimpel & Henney,
1978) though the i.v. route of BCG
injection has been suggested as ineffective
(Germain et al., 1975). This latter difference
from our results can probably be explained
by the dependence ofthe effect on the use
of high doses of BCG. In fact in other
systems, such as infection with Trichinella
8piralis (Jones et al., 1976) or Corynebac-
terium parvurn (Scott, 1974), while the
injection of high doses is largely suppres-
sive, small doses are predominantly stimu-
latory for a variety of responses.
The T-cell independence of these activi-
ties is most important, asMackaness (1 970)
and Evans & Alexander (1972) propose
as a mechanism the following scheme:
T cells specific for the antigens of BCG,
upon reaction with these, secrete mediators
(lymphokines) that provoke the activation
of monocytes and macrophages, which are
then cytostatic. Our results suggest,
however, a more direct influence of BCG-
on the macrophage. It should also be noted
here that in various acute infections sup-
pressive activity appears to be due to
either T cells or macrophages, but not
both together (Jones et al., 1976; Bullock
et al., 1978; Scott, 1974).
It is of considerable importance to
discuss a problem related to the technique
of the cytostatic and suppressive assays
used in our studies. Waldman & Gottlieb
(1973) have presented evidence that
macrophages are able to secrete a factor
that apparently inhibits mitosis, and
Badger et al. (1973) have described a
factor with similar effects secreted by
mitogen-stimulated lymphocytes. Cal-
deron et al. (1974) and Stadecker et al.
(1977) suggested that many of these
inhibitors may in fact have no such effect
in reality, but only modify the incorpora-
tion of [3H]dT into DNA. Large quantities
of endogenously produced dT competing
with [3H]dT could, for example, exert
such an effect. These authors report that
assays using certain tumour cell lines
(such as the EL4) are particularly sensitive
to this type of inhibition. In order to
clarify the possibility that this pheno-
menon occurred in our assay system, we
evaluated the influence of washing the
cultures before labelling, to remove pos-
sible soluble factors liberated by the spleen
cells. This had no significant effect
(results not presented). Such washing,
however, can only eliminate soluble fac-
tors from the culture medium, and would
have no effect on materials already incor-
porated into the cells. It is important to
note in this respect that previous publica-
tionis from our laboratory (Orbach-
Arbouys & Poupon, 1978) and our present
PHA results demonstrate that the spon-
taneous incorporation of [3H]dT by BCG-
treated spleen cells was considerably more
than that of normal populations. This was
the case for whole spleen cell preparations,
as well as for T or adherent cells obtained
from them. It can therefore be asserted
that ifautoinhibition of [3H]dT incorpora-
tion by the spleen cell did not occur this
is even less likely for bystander cells.
The fact that significant in vivo and
in vitro anti-tumour activities were always
paralleled by the generation ofnonspecific
suppressor-cell activity in our system poses
the question of the involvement of the
latter cells in these mechanisms. In effect,
considerable uncertainty surrounds the
role of immune responses, specific or not,
in the control of tumour growth. This
probably arises largely from the great
complexity of the host-tumour relation-
ship, and the participation of numerous
effector and suppressor systems. Consider-
able information exists in the literature on
the effect of suppressor cells on anti-
tumour responses. Anergy, or immuno-
deficiency, have been associated with the
development of suppressor cells in neo-
plasias such as myelomas (Broder et al.,
1975) or Hodgkin's disease (Twomey et al.,
1975). It appears, however, that when the
suppression is specific, suppressor T cells
can be demonstrated. As the injection of
BCG causes the development ofnonspecific
suppressor cells, probably macrophages,
it is reasonable to postulate that the effects
on the host-tumour relationship might be
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different. Some evidence does, in fact,
implicate suppressor cells in tumour con-
trol. For example, the existence of non-
specific concomitant immunity to the
growth of a tumour different from the
primary (Van der G(aarg & McCullagh,
1978) may be due to tumour-induced sup-
pressor cells. It has also been reported
that adherent macrophage-like cells that
can inhibit lymphocyte response to mito-
gens can be correlated with a better prog-
nosis in human cancer (Mikulski & Muggia,
1978), and that cytotoxic T cells appear to
be most effective when in a non-dividing
state (Cantor & Jandinski, 1974). It can
therefore be suggested that a suppressive
activity, that is most conveniently meas-
ured by inhibition of mitogen response,
may be of great importance on account of
its capacity to interfere with the pro-
liferation of a number of cell types,
lymphoid or tumoral. In such a case,
chemotherapy protocols that are designed
to diminish suppressor-cell activity (Or-
bach-Arbouys & Castes, 1979) and studies
using mitogen response as an indicator of
the "immunocompetence" of cancer pa-
tients (Mekori et al., 1974) should be
evaluated with care. A notable lack of
correspondence between the anti-tumour
effects of indomethacin and activation of
depressed mitogen response for example,
has been reported, and severely depressed
mitogen response does not necessarily
mean the existence of a general state of
immune depression (Lynch et al., 1978). It
is obvious that the generation of suppres-
sor cells could be disadvantageous to the
host if they limited specific immune
response, though considering the possible
"blocking" activity of antibody, a prefer-
ential expression of nonspecific mechan-
isms may aid in tumour control. It can be
suggested that excessive production of
suppressor cells, such as might occur when
tumours are particularly large (Poupon
et al., 1976) or when very high doses of
BCG are injected (Olsson et al., 1978),
might facilitate tumouir growth.
In conclusion, we can coinsider 3 possible
mnechanisms by which BCG-induced sup-
pressor cells could be involved in tumour
control. One is that the suppressor cells
are generated in parallel with the actual
effector cells, and might regulate, posi-
tively or negatively, the activity of such
cells. A second possibility is that the
suppressor cells are precursors of the
effector cells, and a third is that the sup-
pressor cells are actually a population of
anti-tumour effector cells. Considering the
parallels that we have found between the
suppressor cell and anti-tumour activities,
we favour the third possibility. Thus the
activity of these cells, though detected as
an in vitro suppression ofvariousresponses,
may be an important mechanism of
tumour control.
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